



GLAND PHARMA LIMITED

April 27, 2023

BSE Limited
Corporate Relationship Department
Phiroze Jeejeebhoy Towers
25th floor, Dalal Street
Mumbai - 400 001
Scrip Code: 543245

National Stock Exchange of India Limited
Listing Department
Exchange Plaza, 5th floor
Plot no. C-1, Block G, Bandra Kurla Complex Bandra
(East), Mumbai - 400 051
Symbol: GLAND (ISIN: INE068V01023)

Dear Sir/Madam,

Sub: Completion of Acquisition of Cenexi - Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Further to our intimations dated 29th November 2022 and 06th January, 2023 regarding the proposed acquisition of Phixen SAS (doing business as ‘Cenexi’ and hereinafter referred as “Cenexi”) and 3 (three) holding companies (holding approximately 6.28% shareholding in Cenexi, hereinafter referred to as “Cenexi Holding Entities”), by Gland Pharma International PTE. Ltd (“Gland Singapore”), a Wholly Owned Subsidiary of Gland Pharma Limited (“Company”), we would like to inform you that the acquisition has been completed on 27th April 2023 in accordance with the terms of the Share Purchase Agreement dated 6th January 2023 between Gland Singapore and FPCI Sino French Midcap Fund as the controlling seller (investment fund managed by Cathay Capital), and other sellers.

Phixen SAS and the Cenexi Holding Entities will now be the wholly owned step-down subsidiaries of the Company. As informed earlier, the aforementioned acquisition has also resulted in indirect acquisition of seven (7) subsidiaries of Cenexi, namely:- (a) Cenexi SAS, (b) Cenexi Services SAS, (c) Cenexi HSC SAS, (d) Cenexi 2 SASU, (e) Cenexi 3 SASU, (f) Cenexi Laboratories Thissen SA and (g) Phineximmo SA.

The details as required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular CIR/CFD/CMD/4/2015 dated September 09, 2015 have been provided along with the intimation dated 29th November 2022.

The Link to access the intimation dated 29th November 2022 is

https://glandpharma.com/images/Gland_Disclosure_Exchanges29112022.pdf

This is for your information and records.

Yours truly,

For Gland Pharma Limited

P Sampath Kumar
Company Secretary and Compliance Officer

Regd. Office:
Survey No. 143-148, 150 & 151, Near Gandimaisamma 'X' Roads
D.P. Pally, Dundigal, Dundigal-Gandimaisamma Mandal
Medchal-Malkajiri District, Hyderabad 500043, Telangana, India
Tel: +91-40-30510999 Fax: +91-40-30510800

Corporate Office:
Plot No. 11 & 84, TSIIIC Phase: IV
Pashamylaram (V), Patancheru (M), Sangareddy District
Hyderabad 502307, Telangana, India
Tel: +91-8455-699999